Nexalin Technology

NXL

Market cap $7.41M

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin's 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group

160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia

HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announced the successful completion of a series of high-level meetings in the United States and China focused on advancing the Company's global clinical strategy for the treatment of Alzheimer's disease and dementia related cognitive decline. These meetings, including a productive Q-Submission interaction with the U.S. Food and Drug Administration (FDA), represent key milestones in the preparation of Nexalin's De Novo application with the FDA for the treatment of Alzheimer's disease.

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin's differentiated, non-invasive DIFS approach

150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment

Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disorders New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disorders

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin's rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its “mood-military-memory” clinical business plan with the FDA by publishing and submitting extensive clinical data.

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating  Nexalin's Deep Intracranial Frequency Stimulation (DIFS™) technology produced positive and objective changes in the participants brain activity measured with advanced neuroimaging. The adult patient population treated in the study suffered from a neurodevelopment disorder known as Attention Deficit Hyperactive Disorder (ADHD).